Cure My Disease

Don't miss your cure!

 Log in / Sign up

Morning vs. afternoon: timing could boost lung cancer treatment

NCT ID NCT07251582

Recruiting now Knowledge-focused Sponsor: Hunan Province Tumor Hospital Source: ClinicalTrials.gov ↗

First seen Dec 04, 2025 · Last updated May 15, 2026 · Updated 27 times

Summary

This study looks at whether getting immunotherapy in the morning or afternoon makes a difference for people with stage II-III lung cancer who are about to have surgery. About 156 participants will receive standard treatment plus immunotherapy at either 8-11 AM or 3-6 PM. The goal is to see if timing affects how well the tumor shrinks before surgery.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RESECTABLE STAGE II-III NON-SMALL CELL LUNG CANCER (NSCLC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Hunan Cancer hospital

    RECRUITING

    Changsha, Hunan, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Hunna Cancer Hospital, Clinical Trails Center

    RECRUITING

    Changsha, Hunan, 410013, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.

RESECTABLE STAGE II-III NON-SMALL CELL LUNG CANCER (NSCLC)